Logo image of NPCE

NEUROPACE INC (NPCE) Stock Fundamental Analysis

USA - NASDAQ:NPCE - US6412881053 - Common Stock

10.2 USD
+0.19 (+1.9%)
Last: 9/26/2025, 8:16:57 PM
10 USD
-0.2 (-1.96%)
After Hours: 9/26/2025, 8:16:57 PM
Fundamental Rating

2

Overall NPCE gets a fundamental rating of 2 out of 10. We evaluated NPCE against 191 industry peers in the Health Care Equipment & Supplies industry. NPCE may be in some trouble as it scores bad on both profitability and health. NPCE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NPCE has reported negative net income.
In the past year NPCE has reported a negative cash flow from operations.
In the past 5 years NPCE always reported negative net income.
NPCE had a negative operating cash flow in each of the past 5 years.
NPCE Yearly Net Income VS EBIT VS OCF VS FCFNPCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

NPCE's Return On Assets of -24.45% is in line compared to the rest of the industry. NPCE outperforms 47.12% of its industry peers.
NPCE has a worse Return On Equity (-133.46%) than 67.02% of its industry peers.
Industry RankSector Rank
ROA -24.45%
ROE -133.46%
ROIC N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NPCE Yearly ROA, ROE, ROICNPCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

Looking at the Gross Margin, with a value of 75.74%, NPCE belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
NPCE's Gross Margin has been stable in the last couple of years.
NPCE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
NPCE Yearly Profit, Operating, Gross MarginsNPCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

NPCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NPCE has more shares outstanding than it did 1 year ago.
NPCE has more shares outstanding than it did 5 years ago.
NPCE has a worse debt/assets ratio than last year.
NPCE Yearly Shares OutstandingNPCE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
NPCE Yearly Total Debt VS Total AssetsNPCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.79, we must say that NPCE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.79, NPCE is doing worse than 65.97% of the companies in the same industry.
A Debt/Equity ratio of 3.02 is on the high side and indicates that NPCE has dependencies on debt financing.
NPCE's Debt to Equity ratio of 3.02 is on the low side compared to the rest of the industry. NPCE is outperformed by 85.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.02
Debt/FCF N/A
Altman-Z -3.79
ROIC/WACCN/A
WACC8.78%
NPCE Yearly LT Debt VS Equity VS FCFNPCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

NPCE has a Current Ratio of 5.47. This indicates that NPCE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.47, NPCE is doing good in the industry, outperforming 79.06% of the companies in the same industry.
A Quick Ratio of 4.51 indicates that NPCE has no problem at all paying its short term obligations.
NPCE has a better Quick ratio (4.51) than 77.49% of its industry peers.
Industry RankSector Rank
Current Ratio 5.47
Quick Ratio 4.51
NPCE Yearly Current Assets VS Current LiabilitesNPCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

NPCE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.94%, which is quite impressive.
Looking at the last year, NPCE shows a very strong growth in Revenue. The Revenue has grown by 23.32%.
NPCE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.67% yearly.
EPS 1Y (TTM)22.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)23.32%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%22.14%

3.2 Future

The Earnings Per Share is expected to grow by 21.17% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 18.68% on average over the next years. This is quite good.
EPS Next Y8.47%
EPS Next 2Y11.97%
EPS Next 3Y19.33%
EPS Next 5Y21.17%
Revenue Next Year20.22%
Revenue Next 2Y12.92%
Revenue Next 3Y16.87%
Revenue Next 5Y18.68%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NPCE Yearly Revenue VS EstimatesNPCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
NPCE Yearly EPS VS EstimatesNPCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NPCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NPCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPCE Price Earnings VS Forward Price EarningsNPCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NPCE Per share dataNPCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as NPCE's earnings are expected to grow with 19.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.97%
EPS Next 3Y19.33%

More info and screens

0

5. Dividend

5.1 Amount

NPCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROPACE INC

NASDAQ:NPCE (9/26/2025, 8:16:57 PM)

After market: 10 -0.2 (-1.96%)

10.2

+0.19 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners60.77%
Inst Owner Change-25.68%
Ins Owners2.49%
Ins Owner Change0.78%
Market Cap337.42M
Analysts84.29
Price Target17.19 (68.53%)
Short Float %4%
Short Ratio5.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.08%
Min EPS beat(2)-14.56%
Max EPS beat(2)14.72%
EPS beat(4)3
Avg EPS beat(4)12.89%
Min EPS beat(4)-14.56%
Max EPS beat(4)30.58%
EPS beat(8)7
Avg EPS beat(8)16.32%
EPS beat(12)11
Avg EPS beat(12)15.67%
EPS beat(16)11
Avg EPS beat(16)8.03%
Revenue beat(2)1
Avg Revenue beat(2)0.48%
Min Revenue beat(2)-0.11%
Max Revenue beat(2)1.08%
Revenue beat(4)2
Avg Revenue beat(4)2.14%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)8.22%
Revenue beat(8)6
Avg Revenue beat(8)3.61%
Revenue beat(12)10
Avg Revenue beat(12)7.12%
Revenue beat(16)12
Avg Revenue beat(16)4.63%
PT rev (1m)0%
PT rev (3m)-2.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.79%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.81
P/FCF N/A
P/OCF N/A
P/B 17.36
P/tB 17.36
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS2.68
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.45%
ROE -133.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.74%
FCFM N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
F-Score5
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 3.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.69%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.47
Quick Ratio 4.51
Altman-Z -3.79
F-Score5
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)83.43%
Cap/Depr(5y)79.26%
Cap/Sales(3y)0.66%
Cap/Sales(5y)0.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y8.47%
EPS Next 2Y11.97%
EPS Next 3Y19.33%
EPS Next 5Y21.17%
Revenue 1Y (TTM)23.32%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%22.14%
Revenue Next Year20.22%
Revenue Next 2Y12.92%
Revenue Next 3Y16.87%
Revenue Next 5Y18.68%
EBIT growth 1Y19.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.5%
EBIT Next 3Y26.38%
EBIT Next 5YN/A
FCF growth 1Y43.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.29%
OCF growth 3YN/A
OCF growth 5YN/A